The DahLIA Trial

DahLIA stands for the Dexmedetomidine to Lessen ICU Agitation study, which was a double-blind, placebo-controlled, RCT conducted at 15 ICUs in Australia and New Zealand from 2011 to 2013.  The study aimed to determine how effective dexmedetomidine is in vented patients with delirium.


  • dexmedetomidine (or placebo) was started at 0.5 ug/kg/h and titrated to rates between 0 to 1.5 to achieve sedation goals; drug was continued until no longer required or up to 7 days
  • Outcomes include ventilator-free hours in the 7 days following randomization plus 21 secondary outcomes (see table below)


  • 75 patients were enrolled, with 3 removed from study group – leaving 39 in treatment and 32 in placebo group
  • dexmedetomidine significantly increased ventilator-free hours (144.8h vs 127.5h)
  • dexmedetomidine significantly reduced time to extubation (21.9h vs 44.3h)
  • dexmedetomidine significantly accelerated resolution of delirium (23.3h vs 40h)



Primary and Secondary Study Outcomes


Kaplan-Meier Analysis of the Proportion of Patients Remaining Intubated During the First 7 Days of the Study




Reade, Michael C. et al. “Effect Of Dexmedetomidine Added To Standard Care On Ventilator-Free Time In Patients With Agitated Delirium”. JAMA (2016): n. page.



Tagged: , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: